GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,954 DKK | +2.04% |
|
-2.57% | -9.30% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Presenter SpeechDeirdre Connelly (Executives)Good afternoon. Welcome to Genmab's 2024 Annual G...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
1,954
DKK
Average target price
2,418
DKK
Spread / Average Target
+23.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.30% | 18.15B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B | |
| -24.71% | 8.24B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Transcript : Genmab A/S - Shareholder/Analyst Call
